Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Azitra Inc.
Bayer invests $8m in medical dermatology specialist Azitra to advance development of OTC and cosmetic products harnessing the skin microbiome.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Emerging Company Profile: Based on its founders’ research at Yale, Azitra is developing topical therapies to treat skin dysbiosis associated with chemotherapy as well as two approaches to atopic dermatitis.
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
- Topical Delivery
- Drug Delivery